Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults

Daniel J. Appelrouth, Sanford Baim, Rowland W. Chang, Mark H. Cohen, DeWitt W. Englund, Bernard F. Germain, Sanford S. Hartman, Adrian Jaffer, Bernard J. Mullen, Fredrica E. Smith

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A six-month, multicenter, double-blind study compared the efficacy and safety of two therapeutic regimens in 332 patients with osteoarthritis. The patients received either 1,000 mg of nabumetone as a single bedtime dose or 900 mg of aspirin in four divided doses. At the end of the study, patients in both treatment groups showed significant improvement from baseline for all five parameters; no statistically or clinically significant differences were observed between the groups. The safety data did reveal clinically and statistically significant differences between the groups. Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent). The results of this study demonstrated that nabumetone, 1,000 mg at bedtime, is as efficacious as aspirin, 900 mg four times daily, produces fewer adverse effects, and is indicated in the treatment of osteoarthritis.

Original languageEnglish
Pages (from-to)78-81
Number of pages4
JournalThe American Journal of Medicine
Volume83
Issue number4 SUPPL. 2
DOIs
StatePublished - Oct 30 1987

Fingerprint

nabumetone
Osteoarthritis
Aspirin
Safety
Therapeutics
Inner Ear
Double-Blind Method

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Appelrouth, D. J., Baim, S., Chang, R. W., Cohen, M. H., Englund, D. W., Germain, B. F., ... Smith, F. E. (1987). Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. The American Journal of Medicine, 83(4 SUPPL. 2), 78-81. https://doi.org/10.1016/0002-9343(87)90600-0

Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. / Appelrouth, Daniel J.; Baim, Sanford; Chang, Rowland W.; Cohen, Mark H.; Englund, DeWitt W.; Germain, Bernard F.; Hartman, Sanford S.; Jaffer, Adrian; Mullen, Bernard J.; Smith, Fredrica E.

In: The American Journal of Medicine, Vol. 83, No. 4 SUPPL. 2, 30.10.1987, p. 78-81.

Research output: Contribution to journalArticle

Appelrouth, DJ, Baim, S, Chang, RW, Cohen, MH, Englund, DW, Germain, BF, Hartman, SS, Jaffer, A, Mullen, BJ & Smith, FE 1987, 'Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults', The American Journal of Medicine, vol. 83, no. 4 SUPPL. 2, pp. 78-81. https://doi.org/10.1016/0002-9343(87)90600-0
Appelrouth, Daniel J. ; Baim, Sanford ; Chang, Rowland W. ; Cohen, Mark H. ; Englund, DeWitt W. ; Germain, Bernard F. ; Hartman, Sanford S. ; Jaffer, Adrian ; Mullen, Bernard J. ; Smith, Fredrica E. / Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. In: The American Journal of Medicine. 1987 ; Vol. 83, No. 4 SUPPL. 2. pp. 78-81.
@article{5b1ddc1970be47e8aedae69293a8165f,
title = "Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults",
abstract = "A six-month, multicenter, double-blind study compared the efficacy and safety of two therapeutic regimens in 332 patients with osteoarthritis. The patients received either 1,000 mg of nabumetone as a single bedtime dose or 900 mg of aspirin in four divided doses. At the end of the study, patients in both treatment groups showed significant improvement from baseline for all five parameters; no statistically or clinically significant differences were observed between the groups. The safety data did reveal clinically and statistically significant differences between the groups. Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent). The results of this study demonstrated that nabumetone, 1,000 mg at bedtime, is as efficacious as aspirin, 900 mg four times daily, produces fewer adverse effects, and is indicated in the treatment of osteoarthritis.",
author = "Appelrouth, {Daniel J.} and Sanford Baim and Chang, {Rowland W.} and Cohen, {Mark H.} and Englund, {DeWitt W.} and Germain, {Bernard F.} and Hartman, {Sanford S.} and Adrian Jaffer and Mullen, {Bernard J.} and Smith, {Fredrica E.}",
year = "1987",
month = "10",
day = "30",
doi = "10.1016/0002-9343(87)90600-0",
language = "English",
volume = "83",
pages = "78--81",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "4 SUPPL. 2",

}

TY - JOUR

T1 - Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults

AU - Appelrouth, Daniel J.

AU - Baim, Sanford

AU - Chang, Rowland W.

AU - Cohen, Mark H.

AU - Englund, DeWitt W.

AU - Germain, Bernard F.

AU - Hartman, Sanford S.

AU - Jaffer, Adrian

AU - Mullen, Bernard J.

AU - Smith, Fredrica E.

PY - 1987/10/30

Y1 - 1987/10/30

N2 - A six-month, multicenter, double-blind study compared the efficacy and safety of two therapeutic regimens in 332 patients with osteoarthritis. The patients received either 1,000 mg of nabumetone as a single bedtime dose or 900 mg of aspirin in four divided doses. At the end of the study, patients in both treatment groups showed significant improvement from baseline for all five parameters; no statistically or clinically significant differences were observed between the groups. The safety data did reveal clinically and statistically significant differences between the groups. Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent). The results of this study demonstrated that nabumetone, 1,000 mg at bedtime, is as efficacious as aspirin, 900 mg four times daily, produces fewer adverse effects, and is indicated in the treatment of osteoarthritis.

AB - A six-month, multicenter, double-blind study compared the efficacy and safety of two therapeutic regimens in 332 patients with osteoarthritis. The patients received either 1,000 mg of nabumetone as a single bedtime dose or 900 mg of aspirin in four divided doses. At the end of the study, patients in both treatment groups showed significant improvement from baseline for all five parameters; no statistically or clinically significant differences were observed between the groups. The safety data did reveal clinically and statistically significant differences between the groups. Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent). The results of this study demonstrated that nabumetone, 1,000 mg at bedtime, is as efficacious as aspirin, 900 mg four times daily, produces fewer adverse effects, and is indicated in the treatment of osteoarthritis.

UR - http://www.scopus.com/inward/record.url?scp=0023633373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023633373&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(87)90600-0

DO - 10.1016/0002-9343(87)90600-0

M3 - Article

C2 - 3318434

AN - SCOPUS:0023633373

VL - 83

SP - 78

EP - 81

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 4 SUPPL. 2

ER -